Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

NCT ID: NCT01864174

Last Updated: 2019-11-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1736 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-20

Study Completion Date

2016-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is determine if Metformin XR monotherapy in subjects with type 2 diabetes is non-inferior to Metformin IR monotherapy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1: Metformin XR and Placebo matching with Metformin XR

Metformin Extended Release (XR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks

Placebo matching with Metformin XR 0 mg tablets by mouth twice daily (BID) for 24 weeks

Group Type ACTIVE_COMPARATOR

Metformin XR

Intervention Type DRUG

Placebo matching with Metformin XR

Intervention Type DRUG

Arm 2: Metformin IR and Placebo matching with Metformin IR

Metformin Immediate Release (IR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks

Placebo matching with Metformin IR 0 mg tablets by mouth twice daily (BID) for 24 weeks

Group Type ACTIVE_COMPARATOR

Metformin IR

Intervention Type DRUG

Placebo matching with Metformin IR

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin XR

Intervention Type DRUG

Metformin IR

Intervention Type DRUG

Placebo matching with Metformin XR

Intervention Type DRUG

Placebo matching with Metformin IR

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glucophage XR Glucophage

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women, aged ≥18 years old at time of enrollment
* Treatment naive subjects with type 2 diabetes mellitus with inadequate glycemic (HbA1c ≥7.0% and ≤9.2% obtained at screening visit) control on diet and exercise alone
* Women must have a negative serum or urine test within 24 hours prior to start of investigational product

Exclusion Criteria

* History of ketoacidosis, lactic acidosis or hyperosmolar non-ketonic coma
* Symptoms of poorly controlled diabetes, including but not limited to marked polyuria and polydipsia with \>10% weight loss during last 3 months
* Serum creatinine ≥1.50 mg/dL (133 μmol/L) for male subjects; serum creatinine ≥1.40 mg/dL (124 μmol/L for female subjects)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bristol-Myers Squibb

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Central Alabama Research

Birmingham, Alabama, United States

Site Status

Terence T. Hart, Md

Muscle Shoals, Alabama, United States

Site Status

Clini Res Advantage Desert Clin Res, Llc

Mesa, Arizona, United States

Site Status

Clinical Res Advantage Central

Phoenix, Arkansas, United States

Site Status

Marin Endocrine Care And Research, Inc.

Greenbrae, California, United States

Site Status

Torrance Clinical Research Institute Inc.

Lomita, California, United States

Site Status

Actca

Los Angeles, California, United States

Site Status

National Research Institute

Los Angeles, California, United States

Site Status

R. Srinivasan, M.D., Inc.

Monterey Park, California, United States

Site Status

Diabetes Medical Center Of California

Northridge, California, United States

Site Status

Valley Clinical Trials

Northridge, California, United States

Site Status

Center For Clinical Trials Of Sacramento, Inc.

Sacramento, California, United States

Site Status

Clinical Research Advantage

Colorado Springs, Colorado, United States

Site Status

Clinical Research Advantage

Colorado Springs, Colorado, United States

Site Status

Colorado Springs Family Practice

Colorado Springs, Colorado, United States

Site Status

Clinical Research Advantage, Inc/Co Springs Health Partners, Briar

Colorado Springs, Colorado, United States

Site Status

Solutions Through Advanced Research, Inc.

Jacksonville, Florida, United States

Site Status

Family Care Partners

Jacksonville, Florida, United States

Site Status

Omega Research Consultants, Llc

Orlando, Florida, United States

Site Status

Palm Harbor Medical Associates

Palm Harbor, Florida, United States

Site Status

Gulfcoast Medical Research Center, Llc

Tampa, Florida, United States

Site Status

Cedar-Crosse Research Ctr

Chicago, Illinois, United States

Site Status

Clinical Research Advantage, Inc./Family Medicine Associates

Evansville, Indiana, United States

Site Status

American Health Network Of In Llc

Muncie, Indiana, United States

Site Status

Columbia Medical Practice

Columbia, Maryland, United States

Site Status

Centennial Medical Group

Elkridge, Maryland, United States

Site Status

Drs. Rodbard And Dempsey

Rockville, Maryland, United States

Site Status

Ny Clinical Trials

New York, New York, United States

Site Status

White Oak Family Physicians, Pa

Asheboro, North Carolina, United States

Site Status

Metrolina Internal Medicine

Charlotte, North Carolina, United States

Site Status

Medical Research Unlimited, Inc.

Cincinnati, Ohio, United States

Site Status

Lion Research

Norman, Oklahoma, United States

Site Status

Lynn Institute of Norman

Norman, Oklahoma, United States

Site Status

Integrated Medical Group Pc / Fleetwood Medical Assoc.

Fleetwood, Pennsylvania, United States

Site Status

Palmetto Clinical Trial Services Llc

Fountain Inn, South Carolina, United States

Site Status

Holston Medical Group

Bristol, Tennessee, United States

Site Status

Dallas Diabetes & Endocrine Center

Dallas, Texas, United States

Site Status

Covenant Clinical Research, Pa

San Antonio, Texas, United States

Site Status

Independence Family Medicine

Virginia Beach, Virginia, United States

Site Status

Local Institution

Edmonton, Alberta, Canada

Site Status

Local Institution

Winnipeg, Manitoba, Canada

Site Status

Local Institution

Brampton, Ontario, Canada

Site Status

Local Institution

Burlington, Ontario, Canada

Site Status

Local Institution

Collingwood, Ontario, Canada

Site Status

Local Institution

London, Ontario, Canada

Site Status

Local Institution

Newmarket, Ontario, Canada

Site Status

Local Institution

Toronto, Ontario, Canada

Site Status

Local Institution

Toronto, Ontario, Canada

Site Status

Local Institution

Québec, Quebec, Canada

Site Status

Local Institution

London, , Canada

Site Status

Local Institution

Brno, , Czechia

Site Status

Local Institution

České Budějovice, , Czechia

Site Status

Local Institution

Krnov, , Czechia

Site Status

Local Institution

Liberec, , Czechia

Site Status

Local Institution

Litomyšl, , Czechia

Site Status

Local Institution

Nový Jičín, , Czechia

Site Status

Local Institution

Ostrava-Kunčice, , Czechia

Site Status

Local Institution

Prague, , Czechia

Site Status

Local Institution

Prague, , Czechia

Site Status

Local Institution

Prague, , Czechia

Site Status

Local Institution

Aschaffenburg, Bavaria, Germany

Site Status

Local Institution

Münster, North Rhine-Westphalia, Germany

Site Status

Local Institution

Leipzig, Saxony, Germany

Site Status

Local Institution

Berlin, , Germany

Site Status

Local Institution

Heidelberg, , Germany

Site Status

Local Institution

Leipzig, , Germany

Site Status

Local Institution

Löhne, , Germany

Site Status

Local Institution

Myen, , Germany

Site Status

Local Institution

Papenburg, , Germany

Site Status

Local Institution

Pirna, , Germany

Site Status

Local Institution

Pécs, Baranya, Hungary

Site Status

Local Institution

Szigetvár, Baranya, Hungary

Site Status

Local Institution

Sátoraljaújhely, Borsod-Abauj Zemplen county, Hungary

Site Status

Local Institution

Hodmezvasarhely, Csongrád megye, Hungary

Site Status

Local Institution

Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary

Site Status

Local Institution

Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary

Site Status

Local Institution

Budapest, , Hungary

Site Status

Local Institution

Budapest, , Hungary

Site Status

Local Institution

Budapest, , Hungary

Site Status

Local Institution

Budapest, , Hungary

Site Status

Local Institution

Budapest, , Hungary

Site Status

Local Institution

Budapest, , Hungary

Site Status

Local Institution

Csorna, , Hungary

Site Status

Local Institution

Debrecen, , Hungary

Site Status

Local Institution

Kecskemét, , Hungary

Site Status

Local Institution

Mosonmagyaróvár, , Hungary

Site Status

Local Institution

Nagykanizsa, , Hungary

Site Status

Local Institution

Orosháza, , Hungary

Site Status

Local Institution

Szentes, , Hungary

Site Status

Local Institution

Székesfehérvár, , Hungary

Site Status

Local Institution

Szobathely, , Hungary

Site Status

Local Institution

Gdansk, Pomeranian Voivodeship, Poland

Site Status

Local Institution

Katowice, Silesian Voivodeship, Poland

Site Status

Local Institution

Bialystok, , Poland

Site Status

Local Institution

Bialystok, , Poland

Site Status

Local Institution

Krakow, , Poland

Site Status

Local Institution

Krakow, , Poland

Site Status

Local Institution

Lublin, , Poland

Site Status

Local Institution

Lublin, , Poland

Site Status

Local Institution

Poznan, , Poland

Site Status

Local Institution

Zamość, , Poland

Site Status

Local Institution

Caguas, PR, Puerto Rico

Site Status

Local Institution

Carolina, PR, Puerto Rico

Site Status

Local Institution

Río Grande, PR, Puerto Rico

Site Status

Local Institution

Las Lomas, San Juan, Puerto Rico

Site Status

Luis Rivera-Colon, Md

Las Lomas, San Juan, Puerto Rico

Site Status

Fb Med Research, Psc

Caguas, , Puerto Rico

Site Status

Policlinica Dr. Luis Rodriguez

Carolina, , Puerto Rico

Site Status

Local Institution

Ponce, , Puerto Rico

Site Status

Ponce School Of Medicine

Ponce, , Puerto Rico

Site Status

Local Institution

Ponce, , Puerto Rico

Site Status

Research & Cardiovascular Corp

Ponce, , Puerto Rico

Site Status

Caparra Internal Med Res Ctr

Río Grande, , Puerto Rico

Site Status

Altamira Family Medicine And Research Institute

San Juan, , Puerto Rico

Site Status

Local Institution

San Juan, , Puerto Rico

Site Status

Local Institution

San Juan, , Puerto Rico

Site Status

The Office Of Miguel Sosa-Padilla, Md

San Juan, , Puerto Rico

Site Status

Local Institution

Alba Iulia, , Romania

Site Status

Local Institution

Bacau, , Romania

Site Status

Local Institution

Bacau, , Romania

Site Status

Local Institution

Baia Mare, , Romania

Site Status

Local Institution

Brasov, , Romania

Site Status

Local Institution

Brasov, , Romania

Site Status

Local Institution

Bucharest, , Romania

Site Status

Local Institution

Bucharest, , Romania

Site Status

Local Institution

Bucharest, , Romania

Site Status

Local Institution

Bucharest, , Romania

Site Status

Local Institution

Bucharest, , Romania

Site Status

Local Institution

Constanța, , Romania

Site Status

Local Institution

Ploieşti, , Romania

Site Status

Local Institution

Satu Mare, , Romania

Site Status

Local Institution

Tg Mures, , Romania

Site Status

Local Institution

Mthatha, Eastern Cape, South Africa

Site Status

Local Institution

Port Elizabeth, Eastern Cape, South Africa

Site Status

Local Institution

Welkom, Free State, South Africa

Site Status

Local Institution

Lyttelton, Gauteng, South Africa

Site Status

Local Institution

Pretoria, Gauteng, South Africa

Site Status

Local Institution

Pretoria, Gauteng, South Africa

Site Status

Local Institution

Durban, KwaZulu-Natal, South Africa

Site Status

Local Institution

Phoenix, Durban, KwaZulu-Natal, South Africa

Site Status

Local Institution

Brits, North West, South Africa

Site Status

Local Institution

Cape Town, Western Cape, South Africa

Site Status

Local Institution

Worcester, Western Cape, South Africa

Site Status

Local Institution

Potchefstroom, , South Africa

Site Status

Local Institution

Monifieth, AFO, United Kingdom

Site Status

Local Institution

Carmarthen, CAT, United Kingdom

Site Status

Local Institution

Fife, FIF, United Kingdom

Site Status

Local Institution

Chippenham, Wiltshire, United Kingdom

Site Status

Local Institution

Chippenham, WLT, United Kingdom

Site Status

Local Institution

Addlestone, , United Kingdom

Site Status

Local Institution

Bath, , United Kingdom

Site Status

Local Institution

Cardenden Fife, , United Kingdom

Site Status

Local Institution

Dundee, , United Kingdom

Site Status

Local Institution

Dundee, , United Kingdom

Site Status

Local Institution

Manchester, , United Kingdom

Site Status

Local Institution

Nuneaton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Czechia Germany Hungary Poland Puerto Rico Romania South Africa United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-004531-23

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CV181-206

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Metformin ER 750 mg Tablets, Fasting
NCT00834743 COMPLETED PHASE1
Metformin ER 750 mg Tablets, Fed
NCT00834613 COMPLETED PHASE1